A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML

Leukemias bearing fusions of the AF10/MLLT10 gene are associated with poor prognosis, and therapies targeting these fusion proteins are lacking. To understand mechanisms underlying AF10 fusion-mediated leukemogenesis, we generated inducible mouse models of AML driven by the most common AF10 fusion proteins, PICALM/CALM-AF10 and KMT2A/MLL-AF10, and performed comprehensive characterization of the disease using transcriptomic, epigenomic, proteomic, and functional genomic approaches. Our studies provide a comprehensive map of gene networks and protein interactors associated with key AF10 fusions involved in leukemia. Specifically, we report that AF10 fusions activate a cascade of JAK/STAT-mediated inflammatory signaling through direct recruitment of JAK1 kinase. Inhibition of the JAK/STAT signaling by genetic Jak1 deletion or through pharmacological JAK/STAT inhibition elicited potent anti-oncogenic effects in mouse and human models of AF10 fusion AML. Collectively, our study identifies JAK1 as a tractable therapeutic target in AF10-rearranged leukemias. STATEMENT OF SIGNIFICANCE Gene fusions of AF10/MLLT10 are recurrent in acute myeloid and lymphoid leukemia and are associated with extremely poor survival outcomes. We show that the JAK1 kinase is required for activation of the AF10 fusion oncotranscriptome and for leukemogenesis. Since a number of JAK/STAT pathways inhibitors are in clinical development or approved for use, our studies may help develop a therapeutic strategy for AF10-rearranged leukemias.

[1]  B. Druker,et al.  Response and Resistance to BCR-ABL1-Targeted Therapies. , 2020, Cancer cell.

[2]  M. Santoro,et al.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues , 2020, Genes.

[3]  Pavel Sumazin,et al.  Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. , 2019, Blood advances.

[4]  A. Drilon.  TRK inhibitors in TRK fusion-positive cancers. , 2019 .

[5]  S. Turner,et al.  The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis , 2019, Cancers.

[6]  Jesse R. Dixon,et al.  Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. , 2019, Experimental hematology.

[7]  Emanuel J. V. Gonçalves,et al.  Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening , 2019, Nature Communications.

[8]  Kendall R. Sanson,et al.  Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities , 2018, Nature Communications.

[9]  S. Armstrong,et al.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. , 2018, Blood.

[10]  Jihoon Kim,et al.  PinAPL-Py: A comprehensive web-application for the analysis of CRISPR/Cas9 screens , 2017, Scientific Reports.

[11]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[12]  Luca Pinello,et al.  Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments , 2017, Nature Protocols.

[13]  K. Winthrop.  The emerging safety profile of JAK inhibitors in rheumatic disease , 2017, Nature Reviews Rheumatology.

[14]  Neville E Sanjana,et al.  Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening , 2016, Nature Protocols.

[15]  B. Geoerger,et al.  Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine , 2017, Molecular therapy. Nucleic acids.

[16]  J. Byrd,et al.  Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia , 2017, British journal of haematology.

[17]  Traci M. Blonquist,et al.  Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. , 2016, Blood.

[18]  E. Macintyre,et al.  NAP1L1‐MLLT10 is a rare recurrent translocation that is associated with HOXA activation and poor treatment response in T‐cell acute lymphoblastic leukaemia , 2016, British Journal of Haematology.

[19]  D. Wechsler,et al.  A Critical Role for CRM1 in Regulating HOXA Gene Transcription in CALM-AF10 Leukemias , 2014, Leukemia.

[20]  H. Kantarjian,et al.  Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. , 2015, Clinical lymphoma, myeloma & leukemia.

[21]  S. Armstrong,et al.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.

[22]  Joshua M. Weiss,et al.  Effects of iron depletion on CALM-AF10 leukemias. , 2014, Experimental hematology.

[23]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[24]  S. Chiaretti,et al.  DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia , 2014, Haematologica.

[25]  O. Bernard,et al.  Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies , 2013, Blood Cancer Journal.

[26]  C. Mecucci,et al.  New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. , 2013, Blood.

[27]  D. Wechsler,et al.  A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. , 2013, Blood.

[28]  F. Locatelli,et al.  Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia , 2013, Leukemia.

[29]  J. Dipersio,et al.  The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis , 2013, British journal of haematology.

[30]  J. Hess,et al.  The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.

[31]  R. Arceci.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study , 2010 .

[32]  S. Raimondi,et al.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.

[33]  P. Aplan,et al.  The role of CALM–AF10 gene fusion in acute leukemia , 2008, Leukemia.

[34]  W. Pear,et al.  Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. , 2008, Blood cells, molecules & diseases.

[35]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[36]  A. Kustanovich,et al.  Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and complex mechanism. , 2006, Cancer genetics and cytogenetics.

[37]  Yi Zhang,et al.  Leukaemic transformation by CALM–AF10 involves upregulation of Hoxa5 by hDOT1L , 2006, Nature Cell Biology.

[38]  James R. Downing,et al.  Annual review of pathology : mechanisms of disease , 2006 .

[39]  W. Kamps,et al.  The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. , 2006, Haematologica.

[40]  E. Macintyre,et al.  CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage , 2003 .

[41]  E. Macintyre,et al.  CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. , 2003, Blood.

[42]  C. Sawyers.  Rational therapeutic intervention in cancer: kinases as drug targets. , 2002, Current opinion in genetics & development.

[43]  公文 和子.  Mixed-lineage leukemia with t(10;11)(p13;q21) : an analysis of AF10-CALM and CALM-AF10 fusion mRNAs and clinical features , 2000 .

[44]  Y. Kaneko,et al.  Mixed‐lineage leukemia with t(10;11)(p13;q21): An analysis of AF10‐CALM and CALM‐AF10 fusion mRNAs and clinical features , 1999, Genes, chromosomes & cancer.

[45]  W. Hiddemann,et al.  MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. , 1998, Blood.